Does Inhaled Busedonide or Fluticasone Impair Adrenal Function?

NCT00560625 | Terminated

• 1 other identifier: 0030-07EMC
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Inhaled corticosteroids are largely used in patients with asthma or chronic obstructive lung diseases. The purpose of this study is to determine if the use of inhaled corticosteroids is associated with suppression of endogenous cortisol production, as seen in patients treated with pharmacologic doses of oral or parenteral steroids.

Conditions

Adrenal Insufficiency

Outcome Measures

Primary Outcomes (1)

• stimulated serum cortisol levels

  within 30 days of treatment

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

hospital-based respiratory diseases clinic

You may qualify if:

• patients receiving inhaled busedonide or fluticasone at daily dose of 200-800 mcg ' for at least 4 weeks

You may not qualify if:

• patients receiving any corticosteroid therapy, except inhaled busedonide or fluticasone.

Sponsors & Collaborators

• HaEmek Medical Center, Israel: lead

Study Sites (1)

Endocrine Institute, Haemek medical Center

Afula, 18101, Israel

Location

MeSH Terms

Conditions

Adrenal Insufficiency

Condition Hierarchy (Ancestors)

Adrenal Gland Diseases; Endocrine System Diseases

Study Officials

• Avraham Ishay, MD

  Endocrine Institute , Haemek Medical Center, Afula. 18101 Israel

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 18, 2007
• First Posted: November 20, 2007
• Study Start: May 1, 2007
• Primary Completion: December 1, 2007
• Study Completion: December 1, 2008
• Last Updated: September 8, 2016

Record last verified: 2016-09

Locations

IL (1)